Executive Officers

Dr. Nakamura is the Chairman and Chief Executive Officer of CMIC HOLDINGS Co., Ltd. He founded Japan’s first Contract Research Organization (CRO) in 1992 and played a key role in establishing the Japan CRO Association alongside three other companies in the field. He served as the Association’s secretariat for five years and later as Chairman from 1999 to 2002, contributing significantly to the growth of the Association and the CRO industry in Japan. The history of CMIC closely mirrors the evolution of CROs in the country. 
　Before founding CMIC, Dr. Nakamura was a project team leader at Sankyo Co., Ltd., where he led the development of Pravastatin, a blockbuster drug used to treat dyslipidemia and prevent cardiovascular disease. 
Dr. Nakamura earned his bachelor’s degree from the Faculty of Pharmaceutical Sciences at Kyoto University and his doctoral degree from the Graduate School of Natural Science and Technology at Kanazawa University. 
　He stated, “CMIC Group pioneered the CRO business in Japan. We began by supporting pharmaceutical development, and today we offer a wide range of services across the entire pharmaceutical value chain—including manufacturing, sales, and marketing—based on our unique ‘Pharmaceutical Value Creator (PVC)’ business model. We also provide services to medical device manufacturers, academia, bio-ventures, and medical institutions, as well as preventive and health-enhancing services to the public. We will continue to create business models that deliver greater value and contribute to the advancement of the pharmaceutical industry.” 

Education: Bachelor’s degree in Pharmaceutical Sciences from Kyoto University/Ph.D. from Kanazawa University

Ms. Oishi is the President and Representative Executive Officer of CMIC HOLDINGS Co., Ltd., responsible for group-wide business execution. She joined CMIC in 1996 as Manager of the Strategy Development Department. Over the past 20 years, she has led International Business and Corporate Development, driving CMIC’s expansion across Japan, Korea, China, Singapore, Taiwan, and other Asia-Pacific regions.

She has also played a key role in international business development, supporting foreign pharmaceutical and biotech companies in initiating regulatory and clinical operations in Japan and Asia.

Ms. Oishi began her career at Nikkei McGraw-Hill, Inc. (now Nikkei Business Publications), as a staff writer for Nikkei Biotech, Japan’s first newsletter specializing in biotechnology. She later gained industry experience at Genzyme Japan, Ltd. and Genentech, Ltd., the Japanese branch of Genentech, Inc. in the U.S. With her broad international experience and strong leadership, she continues to drive CMIC’s global expansion.

Education: Master of Science from the University of Tokyo

Mr. Amano serves as Executive Vice President of CMIC HOLDINGS Co., Ltd. He brings extensive experience across a broad range of areas in the life sciences and healthcare
industry, including corporate strategy, business development, government affairs, market access, and organizational transformation.

Prior to joining CMIC Group, Mr. Amano was responsible for business management and corporate strategy at Roche Diagnostics K.K., where he led initiatives such as corporate integration, organizational restructuring, and AI-enabled business transformation. Before that, he held leadership roles at AbbVie G.K., overseeing Market Access, Business Development, Alliance Management, and External Affairs.
Earlier in his career, Mr. Amano worked at Boston Consulting Group (BCG) and PRTM (now part of PwC), where he advised pharmaceutical companies in Japan and abroad on strategy development and operational transformation across the pharmaceutical value chain, from research and development through sales and marketing. Drawing on his extensive experience in the pharmaceutical and diagnostics industries as well as management consulting, Mr. Amano contributes to the sustainable growth and long-term value creation of the CMIC Group.

Education & Qualifications: Completed the doctoral program at The University of Tokyo.
Ph.D. in Agricultural Sciences.

Mr. Echigo is a Certified Public Accountant (CPA) in Japan. After graduating from the University of Tokyo, he began his career in 2001 as an accounting auditor at Deloitte Touche Tohmatsu LLC and officially registered as a CPA in April 2004.

Until 2019, he was engaged in various financial services including audits under the Financial Instruments and Exchange Act for listed companies, IPO support, M&A advisory, and IFRS consulting. From 2012 to 2016, he was seconded to Deloitte Vietnam’s Hanoi office as part of the Japanese Service Group, where he handled multiple global transactions and organized tax seminars. He also served as sub-leader of the Tax Committee at the Japan Chamber of Commerce and Industry in Vietnam.

Mr. Echigo joined CMIC Group in August 2019 and worked primarily at CMIC CMO Co., Ltd. From June 2021 to September 2024, he served as CFO of CMIC CMO, overseeing corporate management, financial accounting, and the formulation and administration of mid-term management plans and budgets. He was appointed as Corporate Director, Senior Executive Officer Corporate Unit of CMIC HOLDINGS in April 2026, and he has been in charge of corporate management, financial accounting, the formulation and administration of budgets.

Education: Bachelor’s degree from the University of Tokyo
Qualification: Certified Public Accountant (Japan)

Dr. Hamaura has over 34 years of experience at Daiichi Sankyo Co., Ltd., where he worked extensively in formulation development, technology transfer, and technical support for overseas manufacturing sites in Germany, China, Brazil, India, and the United States. During his assignment in the U.S., he served as a CMC Project Manager. He later acted as Global Head of Pharmaceutical Technology across Japan, the U.S., and Germany, overseeing global technical operations. He also served as a JPMA member of the ICH Q8 Expert Working Group.

Since joining CMIC Holdings in 2019, he has led the planning and execution of CDMO business strategy. Leveraging his expertise in formulation development, CMC regulatory affairs, and pharmaceutical technology, he has strengthened business competitiveness across the CMIC Group and expanded partnerships with pharmaceutical companies in Japan and overseas. He currently serves as Representative Director and COO of CMIC CMO Co., Ltd., overseeing business operations and executing growth strategies.

Education & Qualifications: Kyoto University (B.S., M.S.), Tokyo University of Science (Ph.D.), University of London (Postdoctoral Research)

Mr. Matsubara serves as Senior Executive Officer of CMIC HOLDINGS Co., Ltd.

Previously, he held various leadership roles including General Manager of CMIC Inizio, CMIC Healthcare Institute and General Director of CMIC Vietnam. He also served as senior director positions in New Business Development, Finance and Accounting, Corporate General Administration, ICT, Internal Audit and Risk and Crisis Management.

Before joining CMIC in 2008, Mr. Matsubara was Director of Learning and Development at Quintiles Transnational Japan starting in 2006. Prior to that, he worked in the President’s Office at Sankyo Co., Ltd. (now Daiichi Sankyo Co., Ltd.), where he was involved in merger and divestiture negotiations.
With over 30 years of experience in the healthcare industry, Mr. Matsubara contributes to business expansion in Vietnam and neighboring markets.

Education & Qualifications: Bachelor’s degree in Pharmacokinetics from Shizuoka College of Pharmacy (Now The University of Shizuoka School of Pharmaceutical Sciences). Licensed pharmacist.

Mr. Okuda appointed as head of CRO and Consulting Unit of CMIC Holdings Co., Ltd. Additionally, he has been appointed as a board director of CMIC Pharma Science (since 2021). Also, he managed CMIC Shiftzero K.K as joint venture between CMIC Holdings and Shiftzero K.K. as president & representative director (2016-2023).

Prior to joining CMIC group business, he worked for pharmaceutical development as clinical team member and project manager at Roche (Current Chugai) and RPR (current Sanofi) for 15 years as total. After that, he started to work with UK based consulting/project management company (Fulcrum Pharma development Ltd) to establish Japanese branch and subsidiary company with oncology specific CRO as name of Niphix K.K. since 2000-2014.

Specialty will be 1) Strategic pharmaceutical development planning/consulting, 2) Oncology drug development, 3) Project management and 4) corporate management.

He received a Master degree in pharmaceutical science, organic chemistry for Tokyo University of Science, Tokyo Japan.

Education & Qualifications: Master’s degree in Pharmaceutical Science from Tokyo University of Science. Licensed pharmacist.

Mr. Kosaku serves as Senior Executive Officer of CMIC HOLDINGS Co., Ltd. and is currently President of CMIC BIO Co., Ltd. Within the CMIC Group, he has held a wide range of leadership positions, including President of CMIC Pharma Science Co., Ltd., President of CMIC, Inc. (U.S.), Head of the President’s Office, and General Manager of the Corporate Planning Department, as well as being responsible for the International Clinical Development division at CMIC Co., Ltd. Through these roles, he has gained extensive experience across diverse areas of the business.

In addition to his corporate roles, he has contributed to industry development, serving as Chairman of the Japan Association of Contract Laboratories for Safety Evaluation and as Vice Chairman of the Japan CRO Association.

Prior to joining CMIC in 2004, he worked at Japan Tobacco Inc. (Pharmaceutical Division), where he was engaged in clinical development projects as a Project Leader and served as Head of Regulatory Affairs. Leveraging his extensive experience in pharmaceutical development, he continues to contribute to the growth and expansion of the CMIC Group’s business.

Education: Master’s degree in Agricultural and Life Sciences, The University of Tokyo

Mr. Sakazaki currently serves as President of CMIC Healthcare Institute Co., Ltd., a position he assumed on October 1, 2025. He joined the CMIC Group in 2004 as a Site Management Associate (SMA) within the Site Management Organization (SMO) and has since held a wide range of positions across the group. His experience spans multiple business areas, including the CDMO (Contract Development and Manufacturing Organization) business, healthcare services, and CMIC Holdings, providing him with a comprehensive understanding of the industry and its operations.

In addition, he currently serves as Vice Chair of the Japan Association of Site Management Organizations（JASMO）, where he actively contributes to the advancement of the SMO industry as a whole.

Drawing on this diverse background, Mr. Sakazaki leads business development initiatives and oversees organizational management. Prior to joining CMIC, he worked in a completely different industry—experience that has given him a unique perspective and a multifaceted approach, further strengthening his strategic thinking and planning capabilities.

Education & Qualifications: Graduated from Nippon Sport Science University (NSSU), majoring in Sports Science. Holds a national certification as a Career Consultant in the field of human resources.

Title: Executive Officer / Executive Vice President, CMIC Healthcare Institute Co., Ltd.

Biography: Mr. Hasegawa has been engaged in clinical development for over 25 years, starting his career at Fuji Biomedix Co., Ltd. as a Clinical Research Coordinator (CRC) and Study Management Associate (SMA). After working at Sugi Medical Support Co., Ltd., he joined Site Support Institute Co., Ltd. (SSI), where he continued to contribute to the advancement of clinical trial operations.

Since FY2024, Mr. Hasegawa has served as the head of the SSI Company (Site Management Organization business) within CMIC Healthcare Institute Co., Ltd., overseeing the Site Support Solutions business and driving strategic initiatives in clinical site management.

Education & Qualifications:　Bachelor’s Degree in Pharmaceutical Sciences, Setsunan University,

Licensed Pharmacist

Title: Executive Officer / President & CEO, CMIC Pharma Science Co., Ltd.

Biography: Dr. Natsume serves as President & CEO of CMIC Pharma Science Co., Ltd., a non-clinical CRO and member of the CMIC Group.

He joined Hamamatsu Pharma Research in October 2016 and has extensive experience in pharmacological studies using non-human primates and in medical image analysis. Prior to his current roles, Dr. Natsume was engaged in clinical research focused on medical image analysis as an Associated Professor at Fujita Health University. He also held positions in the Radiology Departments of Seirei Hamamatsu General Hospital and Seirei Mikatahara General Hospital in Shizuoka Prefecture.

Education & Qualifications: Dr. Natsume graduated from the Graduate School of Health Sciences at Fujita Health University in 2003. He earned his Ph.D. in Medicine from the Graduate School of Medicine at Mie University in 2007.

Ms. Hara has served as President and Representative Director of OrphanPacific, Inc. since 2021. Established in 2012, OrphanPacific is a licensed pharmaceutical company dedicated to the development and launch of orphan drugs and to delivering treatments to patients with rare diseases.

Ms. Hara joined CMIC Holdings in 2015 and OrphanPacific with a strong desire to help bring life-changing medicines to patients. As project lead and Head of the Research and Development Division, she contributed to obtaining marketing approvals for two orphan drugs. She also served as Head of the Pharmaceutical Affairs Division, overseeing regulatory, safety, and quality assurance operations.

Prior to joining the CMIC Group, Ms. Hara began her career as a clinical pharmacist at a university hospital and transitioned to the healthcare industry in 2004. She previously worked at Otsuka Pharmaceutical Co., Ltd., holding roles across medical science, research and development, and business alliance functions.

Education & Qualifications: Master’s degree in Clinical Pharmacy from Kyoritsu College of Pharmacy (currently the Graduate School of Pharmaceutical Sciences, Keio University) and an MBA from GLOBIS University. Licensed pharmacist.

Position: Executive Officer, Strategic Business Unit

Biography: Ms. Goto is a seasoned business leader with extensive experience in management consulting, global pharmaceuticals, and manufacturing. She began her career at Booz Allen Hamilton (now PwC Strategy&), where she led various projects in business process reengineering and marketing strategy.

At Takeda Pharmaceutical Company and Eli Lilly, she was responsible for product launches, global marketing, and post-merger integration, including an overseas assignment. She later served as an Executive Officer at VALQUA, where she led corporate strategy execution, HR transformation, supply chain optimization, and strategic alliances.

In April 2025, she joined CMIC Holdings. With a life mission to “maximize the potential of people and organizations,” she continues to contribute to the advancement of the healthcare industry and the enhancement of corporate value through her global insights and leadership.

Education: Bachelor’s degree from University of Tokyo; MA from Johns Hopkins University School of Advanced International Studies; MBA with Distinction from Tuck School of Business at Dartmouth

Ms. Sakurai graduated from Hitotsubashi University, majoring in Organizational Development, Change Management, Cultural Shift, and Transformational Leadership. She began her career at RECRUIT Holdings in the HR Business Unit, where she worked for 12 years as an HR consulting sales professional. She supported over 500 clients across various industries, sizes, and growth stages, providing strategic HR consulting and talent planning aligned with each organization’s growth goals.
In addition to client-facing roles, she played a key role in internal talent development and contributed to strategic planning for HR-related products and services. After leaving RECRUIT, she co-founded her own company and spent five years focusing on organizational transformation through the concept of “Being,” helping individuals and organizations evolve from within.
She also supported international companies entering the Japanese market, leading organizational building and scaling from the ground up.
Ms. Sakurai later joined Abbott Japan, a U.S.-based medical device company, where she served for six years as Head of HR and Talent Acquisition. Under her leadership, the Japan team received multiple APAC and global awards for initiatives in diversity & inclusion, branding, international talent acquisition and development, and talent market analysis.
In 2023, she completed the “Fundamental Business Leadership” program at IMD Business School in Switzerland. She joined CMIC Holdings in 2023 as Director of Strategic Group HR, and in 2024, she was appointed CHRO to lead the CMIC Group’s HR strategy.

Education: Bachelor’s degree from Hitotsubashi University

Mr. Ono serves as Head of the Corporate Strategy and Planning Office at CMIC HOLDINGS Co., Ltd. After joining the CMIC Group in 2015, he has driven initiatives aimed at the Group’s overall growth strategy and business development through roles in business development, the CEO Office, and strategic corporate planning. He has been involved in a wide range of strategic projects, including M&A, capital and business alliances, the establishment of joint ventures, and the launch of new companies. In addition, within the CRO business—primarily across Asian markets excluding Japan—he has supported the formulation of business strategies for regional sites from headquarters, working to strengthen cross-regional collaboration and build a solid business foundation. Prior to joining the CMIC Group, he worked at FUJIFILM Corporation, where he was engaged in domestic and international business planning, marketing, and corporate management. He subsequently gained further experience in business strategy and marketing at MISUMI Group Inc.

Education: Bachelor’s degree from Hitotsubashi University, MBA, Duke University

Mr. Morooka joined CMIC CMO Co., Ltd. in 2019 and has consistently been engaged in business development, including two years overseeing business development activities for a U.S.-based manufacturing site.

Prior to joining CMIC, he spent 25 years at Zeria Pharmaceutical Co., Ltd., where he was involved in a wide range of clinical development activities across Japan, Europe, and the United States. His experience spans roles from Clinical Research Associate (CRA) to project management and business development.

In addition, he worked on new business development initiatives outside the prescription pharmaceutical field in both the U.S. and Asian regions.

From 2024, Mr. Morooka was seconded to the Japan Agency for Medical Research and Development (AMED), where he was responsible for initiatives to strengthen the drug discovery venture ecosystem. Through this role, he built extensive networks with diverse stakeholders across the drug discovery and innovation ecosystem. Leveraging his broad experience and strong professional network, he actively contributes to the promotion of CMIC Group’s business initiatives. In April 2026, he assumed responsibility for the President’s Office.

Education: Master’s degree in Pharmaceutical Sciences, Kumamoto University
Licensed Pharmacist

Ms. Kawai has had a distinguished career in international finance and asset management, with professional experience at Nomura Research Institute, McKinsey & Company (Paris), and SG Warburg. She served as a Senior Fund Manager at the Bank for International Settlements (BIS) and subsequently as Head of Pension Fund Management at the Organisation for Economic Co-operation and Development (OECD).

She has also held the positions of Professor and Professor Emeritus at Kyoto University, where she developed extensive expertise in governance practices at international institutions and private-sector organizations.

She currently serves as an Outside Director of Mitsui Fudosan Co., Ltd., Daiwa Securities Group Inc., and DMG MORI Co., Ltd.

Mr. Alberni serves as Leader of PwC Japan Health Industries and as a Principal at PwC Consulting, where he provides consulting services to the healthcare industry in Japan. He previously served as a Partner at PRTM Management Consulting and as Representative of PRTM Japan and brings extensive experience in the development of global strategies within the pharmaceutical and healthcare sectors.

Based in the United States, he currently supports Japanese companies in corporate strategy, organizational transformation, and operational reform.

Mr. Engen is the Chief Executive Officer of Renexes LLC and brings extensive experience in the biopharmaceutical markets in both Japan and the United States. He has held a number of senior leadership positions, including Vice President and Representative Director of Shire Japan, Chief Executive Officer of Solasia Pharma, and President of Mundipharma Japan, and has been deeply involved in the management of multiple companies across Japan and the broader Asia region.

With over 25 years of experience in the biopharmaceutical sector, he has been engaged in executive management, mergers and acquisitions, and licensing activities. He is fluent in Japanese and maintains a strong network with Japanese companies.

Mr. Mochizuki joined CMIC in 2005 as an Executive Officer for internal control and corporate finance. In 2012, he was appointed Chief Financial Officer (CFO), and since then has been responsible for overseeing the company’s financial operations. In 2024, he was appointed the Representative Director, Vice Chairman.

Prior to joining CMIC, Mr. Mochizuki served as a corporate officer for finance at a U.S.-based networking device venture company, where he led the company to a successful IPO on the Tokyo Stock Exchange. He has held various senior finance roles, contributing to corporate strategy development and cross-functional collaboration from a financial perspective.

Education: Bachelor of Arts in Commerce, Waseda University

Dr. Hamaura has over 34 years of experience at Daiichi Sankyo Co., Ltd., where he worked extensively in formulation development, technology transfer, and technical support for overseas manufacturing sites in Germany, China, Brazil, India, and the United States. During his assignment in the U.S., he served as a CMC Project Manager. He later acted as Global Head of Pharmaceutical Technology across Japan, the U.S., and Germany, overseeing global technical operations. He also served as a JPMA member of the ICH Q8 Expert Working Group.

Since joining CMIC Holdings in 2019, he has led the planning and execution of CDMO business strategy. Leveraging his expertise in formulation development, CMC regulatory affairs, and pharmaceutical technology, he has strengthened business competitiveness across the CMIC Group and expanded partnerships with pharmaceutical companies in Japan and overseas. He currently serves as Representative Director and COO of CMIC CMO Co., Ltd., overseeing business operations and executing growth strategies.

Education & Qualifications: Kyoto University (B.S., M.S.), Tokyo University of Science (Ph.D.), University of London (Postdoctoral Research)

Mr. Saito joined CMIC in 2019 and has led the Legal and Compliance team at CMIC Group, supporting the company from both perspectives of guardian and business partner. He is an attorney admitted in Japan and the State of New York, USA. Mr. Saito started private practice as a lawyer in 1992 and has worked at multiple large US and Japanese law firms including a career in the USA from 1997 to 2002. After working at CITY YUWA Partners as a partner, Mr. Saito joined GE as an in-house counsel in 2007 and then worked at Shinsei bank as a manager of legal division, AIG Japan as a general counsel until 2018. Besides legal practice, Mr. Saito serves as a mediator at Tokyo Bar Association, Trust Association, Nuclear Damage Compensation Dispute Resolution Center and as a member of Financial ADR committee at Financial Services Agency (FSA). Mr. Saito has been teaching business law at Meiji University Law School and Business School, and also financial law at Tsukuba University Law School since 2013.

Mr. Sano is the Academy Head of CMIC HOLDINGS Co., Ltd.

Prior to joining CMIC, Mr. Sano served as Executive Vice President and Director at SAGAN DREAMS CO., LTD, an operating company of a professional football team.

Mr. Sano joined CMIC in 2008 as a President of CMIC-MPSS Co. Ltd., currently a joint venture company of CMIC Ashfield Co., Ltd., that focuses on Contract Sales Organization (CSO) business within CMIC Group. Since 2013, he has held various senior management positions, such as Head of Secretarial Office, Human Capital Development Center Director and Liaison Officer.

Mr. Sano has his bachelor’s degree of Faculty of Engineering from Kyoto University.

Dr. Shimoto is the Chairman of Orphanpacific Inc. and the Division Director of Market Solution business unit of CMIC HOLDINGS. He joined the company in June 2021. Prior to joining CMIC, Dr. Shimoto served as Executive Vice President, Clinical Development at Daiichi Sankyo RD Novare Co., Ltd., and was responsible for oversight of clinical studies/clinical researches execution and corporate management. He also had served as Vice President of Global Project Management and Asia Development at Daiichi Sankyo Co., Ltd., and was responsible for portfolio/project management of R&D and clinical study implementation in Asian region, respectively. He provided scientific/regulatory input to the development of an antisense oligonucleotide for duchenne muscular dystrophy, as External Director of Orphan Disease Treatment Institute. He studied abroad at the University of Tokyo in 1988-1989, and at University of Michigan in 1992-1993 as a researcher. He also worked in US as a project manager at Daiichi Pharmaceutical Inc. in 1999-2005.

Dr. Shimoto received a master’s degree in Pharmacy from Chiba University and a doctoral degree from the University of Tokyo.

Mr. Kuwajima joined CMIC in 2019 and is currently the Corporate Director and Vice Chairman of CMIC HOLDINGS Co., Ltd, responsible for strategic management of CMIC Group.

He is also the Chairman of CMIC HealthCare Institute Co., Ltd., which is one of the subsidiaries of CMIC Group which focuses on site and patient activities such as Site Management Organization (SMO) and other healthcare related services. Additionally, he is the Representative Director and Chairman of CMIC Career Co., Ltd., which offers human resource services focusing on the pharmaceutical industry.

In 1997, he was Representative Director of IBRD JAPAN Co., Ltd., which is a CRO company established in 1992. He also served on the board of the Japan CRO Association. In 2006, Mr. Kuwajima established and became the president of Medi-Skette Corporation, a company that provides support for collecting data from clinical trials, post-marketing surveillance and other pharmaceutical studies. Prior to joining CMIC, he served as an Executive Officer at MEDICEO CORPORATION, where he was in charge of Academia Support, Sales Division.

With his broad experience and strong leadership, he brings new ideas and actively takes the lead in creating innovative healthcare services in CMIC Group.

Mr. Kuwajima has a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

Mr. Kuwajima joined CMIC in 2019 and is currently the Corporate Director and Vice Chairman of CMIC HOLDINGS Co., Ltd, responsible for strategic management of CMIC Group.

He is also the Chairman of CMIC HealthCare Institute Co., Ltd., which is one of the subsidiaries of CMIC Group which focuses on site and patient activities such as Site Management Organization (SMO) and other healthcare related services. Additionally, he is the Representative Director and Chairman of CMIC Career Co., Ltd., which offers human resource services focusing on the pharmaceutical industry.

In 1997, he was Representative Director of IBRD JAPAN Co., Ltd., which is a CRO company established in 1992. He also served on the board of the Japan CRO Association. In 2006, Mr. Kuwajima established and became the president of Medi-Skette Corporation, a company that provides support for collecting data from clinical trials, post-marketing surveillance and other pharmaceutical studies. Prior to joining CMIC, he served as an Executive Officer at MEDICEO CORPORATION, where he was in charge of Academia Support, Sales Division.

With his broad experience and strong leadership, he brings new ideas and actively takes the lead in creating innovative healthcare services in CMIC Group.

Mr. Kuwajima has a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

Mike is the President & CEO of CMIC, INC., located in Hoffman Estates, Illinois (near Chicago O’Hare Airport), an emerging lab CRO and a service provider specialized in BioAnalysis for supporting pre-clinical TK and clinical PK/PD biomarker studies during development of biologics and oligonucleotides as well as small molecule pharmaceuticals. The company started lab operation at its purpose-built GLP facility as JCL Bioassay USA in 2010, and joined CMIC Group through acquisition in 2015. Since then, Mike has been in this Chicago-based leadership position, and also led strategic facility investment in 2017, along with CMIC’s new U.S. client base expansion after acquisition and integration.
Prior to joining CMIC, Mike was the Deputy General Manager of GE Healthcare’s CT/MRI contrast media in-vivo diagnostics and PET/SPECT radio-pharmaceuticals division in Japan, where he was the first employee soon after GE’s acquisition of former Amersham, and was responsible for establishing a new pharmaceutical operation reporting into GE Healthcare’s U.K. Headquarters. While at GE, Mike was not only leading a number of pharmaceutical and IP licensing (e.g., Daiichi Sankyo, Sumitomo Chemical, Fujifilm) and regulatory authority (PMDA/MHLW) negotiations, but also was heavily involved in clinical trials (GCP) and CMC development (GMP) both globally (Phase III ~ Post-approval) and regionally(Asian-Caucasian bridging Phase I~II).
Mike started his 30-year professional career as a tissue culture and genomics scientist at JT (now a.k.a. Akros) genetic engineering lab, and later spent five years in New York and San Francisco as JT’s recombinant DNA business development manager. Mike earned bachelor’s and master’s degrees in agricultural biosciences from University of Tokyo. He also completed GE’s internal executive training program at its Crotonville, New York main campus.

Mr. Keino is the President of CMIC Healthcare Co., Ltd. and Senior Vice President of CMIC HOLDINGS Co., Ltd. He joined the CMIC CRO business development group in 1999. Since joining CMIC, he has held leadership roles related to the SMO business startup (in 2001), the CRO business startup in China (in 2005), the SMO business turnaround (in 2007), and the management of the Asian business (in 2010). Since 2015, he has managed CMIC’s Healthcare business. As President of CMIC Healthcare Co., Ltd., Mr. Keino’s mission is to facilitate healthcare innovation by providing comprehensive service solutions in the areas of patient record keeping and patient information sharing. Prior to joining CMIC, Mr. Keino worked at the administrative scrivener’s office supporting documentation and submission of certifications and registrations for medical devices. Mr. Keino received a bachelor’s degree in French Literature from Meiji Gakuin University.

Mr. Lee has been a Representative Director and President of CMIC CMO Korea since 2014. He is responsible for manufacturing supervision (Ointment/Cream/Gel) and quality assurance/control. He joined CMIC CMO Korea as a plant manager and director of production in 2008. He has extensive experience in GMP manufacturing and quality assurance/control in the pharmaceutical industry. Prior to joining CMIC CMO Korea, Mr. Lee served as senior leader and senior manager for quality assurance/control of Korea Otsuka Pharmaceuticals Co., Ltd. and was responsible for managing application and approval work of Asian and Arab registrations. In this capacity, he supervised manufacturing, evaluated operations, and oversaw facilities and equipment capital investments. Mr. Lee started his career in quality assurance/control at SAMIL Pharmaceutical Co. in 1992, helping the company obtain certifications of domestic and foreign GMP. Subsequently, he managed the NDA registration process for drug exportation and GMP inspection of affiliate companies Korea Otsuka Pharmaceuticals and CHOONGWAE Pharmaceuticals. Mr. Lee earned a bachelor’s degree in Pharmacy from Sungkyunkwan University and completed doctoral degree coursework in Pharmacy at Sungkyunkwan University. Pharmacist.

April 1968 Joined The Sanwa Bank, Ltd. (currently, The Bank of Tokyo-Mitsubishi UFJ, Ltd.)
June 1994 Director of The Sanwa Bank, Ltd.
May 1997 Managing Director of The Sanwa Bank, Ltd.
June 1999 President of Sanwa Capital Finance Ltd. (Mitsubishi UFJ Capital Co., Ltd.)
June 2005 The Chairman and Director of Ask Planning Center, Inc.
July 2005 The Chairman of CREEK & RIVER Co., Ltd.
March 2011 The President of Medical Principle Co., Ltd. (to present)
December 2014 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
June 2017 Chairman and Director, ASK HOLDINGS, INC. (to present)
June 2017 Chairman and Director, Wealth Management, Inc. (to present)

Status of Important Concurrent Posts
-The President of Medical Principle Co., Ltd.
-The Chairman and Director of ASK HOLDINGS, INC.
-The Chairman and Director of Wealth Management, Inc.

December 1973 The University of Tokyo
April 1983 Department of Surgery II, Faculty of Medicine, University of Yamanashi
April 1993 Joined Hoechst Japan Co., Ltd., as a head of Medical Affairs Office
January 2005 Joined GlaxoSmithKline K.K.
September 2011 Professor of Departmen Faculty of Medicine, University of Yamanashi
September 2014 Professor of Department of Advanced Biomedical Research in Faculty of Medicine, University of Yamanashi (to present)
April 2015 Vice President of University of Yamanashi (to present)
December 2016 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
Status of Important Concurrent Posts
－Program Officer, Japan Agency for Medical Research and Development
－Visiting Professor, Juntendo University School of Medicine
－Visiting Professor, Ehime University School of Medicine

April 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare) July 2000 Director, Public Relations Office, General Coordination Division, Minister’s Secretariat, Ministry of Health and Welfare
July 2004 Director, National Health Insurance Division and Director, General Affairs Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare
July 2009 Deputy Director-General (in charge of Medical Insurance, Health Policy, Health Care and Long-term Care Integration), Ministry of Health, Labour and Welfare
Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social Security), Ministry of Health, Labour and Welfare
July 2014 Director General, Health Insurance Bureau, Ministry of Health, Labour and Welfare
June 2016 Director-General for Regional Revitalization, Headquarters for Overcoming Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat
August 2016 Retired from Cabinet Secretariat
Status of Important Concurrent Posts
－Visiting Professor, Saku University
December 2018 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)

October 1981 Joined Nomura Research Institute, Ltd.
September 1985 Management Consultant, McKinsey & Company
October 1986 Fund Manager, Mercury Asset Management plc, SG Warburg
November 1995 Chief Investment Officer (CIO), Yamaichi Regent ABC Polska
July 1998 Joined Bank for International Settlements
October 2004 Senior Pension Fund Administrator, Organisation for Economic Co-operation and Development (OECD)
March 2008 Representative, Kawai Global Intelligence
April 2012 Professor, Institute for the Promotion of Excellence in Higher Education, Kyoto University
April 2013 Professor, Institute for Liberal Arts and Sciences, Kyoto University
April 2014 Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University (to present)
December 2017 Audit & Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Status of Important Concurrent Posts
-Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University
-Director, The Outlook Foundation
-Director, The Grew Bancroft Foundation
-Outside Director, Nikko Asset Management Co., Ltd.
December 2017 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Dr. Mayer is the External Corporate Director of CMIC HOLDINGS Co., Ltd.. Dr. Mayer received his BA and Ph.D. from the University of California, Berkeley. After serving as President at Berkeley Antibody Company, and Vivigen, Inc., he studied Japanese at Keio University in Tokyo and was also a research student at Keio University’s Business School and the National Children’s Hospital. Upon returning to the US, he worked in the San Francisco office of McKinsey & Company before establishing his own management consulting practice in the San Francisco Bay Area in 1995. He has spent the last 25 years focusing on healthcare business strategy in the US and Japan and has helped numerous US and European companies with their Japan development strategies, as well as Japanese companies with their work in the US. In addition to biopharmaceutical development, Dr. Mayer also works in the areas of population health management and healthcare IT.

April 1972 Joined Mitsui Pharmaceuticals, Inc.
January 2001 Joined Nihon Schering K.K. (currently Bayer Yakuhin, Ltd.)
August 2005 Joined the Company, General Manager in charge of the Business Promotions Department (Tokyo)
July 2011 General Manager, Quality Management Promotion Office, Clinical Development Div. I, the Company
October 2012 General Manager, Resource Management Office, CMIC Co., Ltd.
October 2015 Business Planning Division, Site Support Institute Co., Ltd.
August 2018 Business Development Division, Site Support Institute Co., Ltd.(to present)
December 2018 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

April 1983 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)
September 2019 Joined CMIC Co., Ltd., General Manager in charge of QMS Department, QM Div.
January 2022 Director, and Head of Real & Virtual Lab, CMIC HealthCare Institute Co., Ltd.
December 2022 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Kei Hata
External Audit and Supervisory Board Member

April 1984 Admitted to the TOKYO BAR Association -Joined Kazama & Co. Law Offices (currently Hata & Co. Law Offices)
December 2015 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

November 1977 Joined Showa Audit Corporation (currently Ernst & Young ShinNihon LLC)
August 1981 Registered as Certified Public Accountant
August 2008 Executive Director, Ernst & Young ShinNihon LLC
August 2012 Senior Managing Director, Ernst & Young ShinNihon LLC
July 2014 Executive Vice President, Ernst & Young ShinNihon LLC
July 2016 Established Hidetoshi Watanabe Certified Public Accountant Office (to present)
June 2017 Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.(to present)
Status of Important Concurrent Posts
-Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.
December 2018 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

October 1991 Joined Aoyama Audit Corporation(currently PricewaterhouseCoopers Aarata LLC)
March 1997 Joined PwC Consulting Co., Ltd. (currently IBM Japan Ltd)
October 1999 Joined ChuoAoyama Audit Corporation
March 2001 Joined Sanwa Capital Finance Ltd. (currently Mitsubishi UFJ Capital Co., Ltd.)
December 2002 Joined Phoenix Capital Co., Ltd.
March 2003 Director, Phoenix Capital Co., Ltd.
April 2006 Representative Director, Ascent Partners (to present)
June 2015 Outside Corporate Auditor, MORITA HOLDINGS CORPORATION (to present)
June 2017 Outside Audit & Supervisory Board Member, Wealth Management, Inc. (to present)

Significant concurrent positions outside the Company:
Representative Director, Ascent Partners
Representative Corporate Auditor, MORITA HOLDINGS CORPORATION
Outside Audit & Supervisory Board Member, Wealth Management, Inc.

March 2000 Resigned from TONETS CORPORATION
April 2000 Joined CMIC HOLDINGS Co., Ltd.
March 2001 Board Director
October 2002 Managing Director and CFO of CMIC HOLDINGS Co., Ltd. Division head of Administration Division and Director of Finance and Accounting Department
October 2003 Vice President, Director, and CFO of CMIC HOLDINGS Co., Ltd.
October 2004 Vice President, Representative Director and CFO of CMIC HOLDINGS Co., Ltd.
December 2007 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2009 Board Director of CMIC HOLDINGS Co., Ltd.
December 2010 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2015 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Dr. Suzuki has been the Chief Scientific Officer of CMIC HOLDINGS since October 2014. He is responsible for evaluating new businesses, especially in next-generation antibodies, medium- and large-molecule drugs, and diagnostics and biomarkers, from the scientific point of view. Prior to joining CMIC, Dr. Suzuki served in several roles at Takeda Pharmaceuticals beginning in 1980. As Director of Frontier Research Laboratories, he led several projects for the development of regenerative medicines, nucleic acid medicines and peptide medicines. As the pharmacology group leader, Dr. Suzuki also led projects for the development for GnRH antagoists, insulin secretagogues, and small-molecule G-protein coupled receptor of anti-obesity drugs. His involvement in the development of Sandwich-ELISA, the measurement system of Amyloid β40/42, contributed to the pathology understanding of Alzheimer’s disease. Dr. Suzuki said that he would contribute to the innovative drug development for new modalities like next-generation antibodies, cyclic peptide and nucleic acid. Dr. Suzuki earned a master’s degree in Chemistry from Kyoto University and a doctoral degree from Gifu Pharmaceutical University. He was a visiting research fellow at Case Western Reserve University in Ohio in 1993.

November 1989 Passed the national bar examination
April 1992 Registered as attorney at law, Daini Tokyo Bar Association Joined Hamada &
Matsumoto (currently Mori Hamada & Matsumoto)
April 2005 Partner, Mori Hamada & Matsumoto 
June 2019 Outside Corporate Auditor, KITO CORPORATION 
June 2022 Outside Director, Audit and Supervisory Committee Member, SPARX Group
Co., Ltd. (to present)
December 2022 External Audit and Supervisory Board Member of CMIC HOLDINGS Co.,
Ltd. (to present)
January 2023 Senior Counsel, Mori Hamada & Matsumoto
July 2023 Outside Director, The Prudential Life Insurance Company, Ltd. (to present)
January 2024 Special Counsel, Gaien Partners (to present)
June 2024 Outside Audit & Supervisory Board Member, Daifuku Co., Ltd. (to present)